YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Ono Pharmaceutical Co. (OPHLF) shares rallied 9.2% in the last trading session to close at $14.61. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the…
Korro Bio, Inc. (KRRO) shares ended the last trading session 17.6% higher at $12.99. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.4% gain o…
Industry veterans from Sunrise BioVentures to provide strategic and operational support as the company advances its JUN_01 siRNA cardiometabolism program toward Phase 1 clinical trials and progresses its RESET Platform pipeline SAN FRANCIS…
Colorful stock market chart with rising and falling lines behind bold “Insider Trades” text, symbolizing investor activity and insider buying trends. Key Points Insiders were active in Q1, but insider buying isn't enough to warrant an inve…
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is th…
Korro Bio, Inc. (KRRO) came out with a quarterly loss of $5.32 per share versus the Zacks Consensus Estimate of a loss of $1.93. This compares to a loss of $2.26 per share a year ago. These figures are adjusted for non-recurring items. Thi…
United Therapeutics UTHR shares rallied 10.7% in the last trading session to close at $529.17. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stoc…
Financing led by new investor Venrock Healthcare Capital Partners, with participation from new and existing investors Proceeds support the achievement of value inflection points for multiple RNA editing programs including reporting clinica…
CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announce…
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Korro Bio, Inc. is next on our list of best biotech stocks. TheFly reported on January 29 that H.C. Wainwright upgraded KRRO from Neutral to Buy with a $20 pri…
Korro Bio, Inc. (KRRO) shares soared 13.9% in the last trading session to close at $13.31. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 45.9% gain over the p…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Barclays upgraded Zillow Group(ZG) to Equa…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Barclays upgraded Zillow Group(ZG) to Equa…
CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on T…
Korro Bio (KRRO) stock saw heavy trading activity after the company announced its lead candidate KRRO-110 failed to reach key protein targets in a Phase 1/2a clinical trial. The disappointing data prompted a major shift in strategy for the…
Stocks were swept up in a broad-based selloff on Thursday. - AFP via Getty Images It was an unusually rough day on Wall Street. Major U.S. equity indexes, including the S&P 500 index, Nasdaq Composite Index, Dow Jones Industrial Average an…
Korro Bio's (KRRO) move to prioritize GaINac-conjugated programs that target the liver is the pragma PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
[Colorful DNA helix] Stanislaw Pytel/DigitalVision via Getty Images Korro Bio (KRRO [https://seekingalpha.com/symbol/KRRO]) shares fell following results from its early-stage clinical trial of KRRO-110, aimed at treating patients with alph…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Wedbush upgraded DoorDash (DASH) to Outper…
The small cap-focused Russell 2000 index has spent years lagging behind the larger S&P 500 and Nasdaq 100 indexes, but in third-quarter 2025 it took a big leap back to parity with large caps. Thanks to interest-rate-cut bets and optimism a…
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied…
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences for the month of Septembe…
[Small Cap write on sticky notes isolated on Office Desk. Stock market concept] syahrir maulana/iStock via Getty Images The Russell 2000 (IMW) is close to its strongest relative performance compared to the S&P 500 (SP500 [https://seekingal…
[Novo Nordisk sign on building, Danish pharmaceutical healthcare giant, production innovative drugs, obesity treatment Ozempic, pharmaceutical company innovation, Mainz, Germany June 15, 2024] Victor Golmer In the aftermath of several deal…
—Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025 —Streamlining operations and focusing on delivering potential value generating program miles…
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly pr…
—Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025 —U.S. Food and Drug Administration (FDA) Granted Orphan…
CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly pr…
CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly pre…
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications Wednesday, Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE:NVO) to advance the deve…
Biotech veteran brings more than two decades of life science experience to Korro’s Board CAMBRIDGE, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new cl…
Korro will be focused on advancing a wholly owned portfolio of RNA editing programsPost-transaction cash of approximately $170 million expected to fund operations into 2026Funds multiple potentially value-creating milestones, including adv…
Korro will be focused on advancing a wholly owned portfolio of RNA editing programsPost-transaction cash of approximately $170 million expected to fund operations into 2026Funds multiple potentially value-creating milestones, including adv…